Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market: LucPosted by Rohini Chaudhari on February 4th, 2020 Exocrine Pancreatic Insufficiency (EPI) therapeutics and diagnostics market is expected to register robust growth during 2017-2025. The market is expected to garner 7.2% CAGR during this period. It is projected to reach a valuation of US,414.4 mn by 2025. Its valuation in 2016 stood at US,397.5 mn. So What’s Driving the Projected Growth? Rising cases of diabetes are expected to fuel growth of the EPI therapeutics and diagnostics market. According to the latest report by the American Diabetes Association, the total population of diabetics around the world is expected to reach 366 mn by 2030. According to Global diabetes community in the UK, 25% to 50% of insulin dependent diabetics developed EPI at a later stage. Diabetes also shares a strong correlation with cystic fibrosis. The rise in technological advancements like big data are expected to propel diagnosis of cystic fibrosis. It is estimated that nearly 90% of the patients with cystic fibrosis develop EPI. The rising cases of diabetes, the increasingly sedentary lifestyle, and worsening environmental conditions are expected to drive growth of the EPI therapeutics and diagnostics market in the near future. Like it? Share it!More by this author |